-
1دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
2دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
3دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
4دورية أكاديمية
المؤلفون: Barlaam B; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Casella R; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Cidado J; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Cook C; Oncology R&D, AstraZeneca, Macclesfield, SK10 2NA, United Kingdom., De Savi C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Dishington A; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Donald CS; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Drew L; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Ferguson AD; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States., Ferguson D; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Glossop S; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Grebe T; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Gu C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Hande S; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Hawkins J; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Hird AW; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Holmes J; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Horstick J; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Jiang Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China., Lamb ML; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., McGuire TM; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Moore JE; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., O'Connell N; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States., Pike A; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Pike KG; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Proia T; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Roberts B; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., San Martin M; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Sarkar U; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Shao W; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Stead D; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Sumner N; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Thakur K; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Vasbinder MM; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Varnes JG; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Wang J; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Wang L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China., Wu D; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Wu L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China., Yang B; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Yao T; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China.
المصدر: Journal of medicinal chemistry [J Med Chem] 2020 Dec 24; Vol. 63 (24), pp. 15564-15590. Date of Electronic Publication: 2020 Dec 11.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
مواضيع طبية MeSH: Cyclin-Dependent Kinase 9/*antagonists & inhibitors , Protein Kinase Inhibitors/*chemistry , Pyridines/*chemistry, Animals ; Apoptosis/drug effects ; Binding Sites ; Cell Line, Tumor ; Cyclin-Dependent Kinase 9/metabolism ; Dogs ; Drug Evaluation, Preclinical ; Half-Life ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/pathology ; Humans ; Mice ; Molecular Docking Simulation ; Myeloid Cell Leukemia Sequence 1 Protein/metabolism ; Protein Kinase Inhibitors/metabolism ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyridines/metabolism ; Pyridines/pharmacology ; Pyridines/therapeutic use ; Rats ; Solubility ; Structure-Activity Relationship ; Xenograft Model Antitumor Assays
-
5دورية أكاديمية
المؤلفون: Cogswell TJ; School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, U.K., Donald CS; Lucideon Limited., Queens Road, Penkhull, Stoke-on-Trent, Staffordshire, ST4 7LQ, U.K., Marquez R; School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, U.K.; School of Physical and Chemical Sciences, University of Canterbury, Christchurch, 8140, New Zealand.
المصدر: Beilstein journal of organic chemistry [Beilstein J Org Chem] 2020 Jan 28; Vol. 16, pp. 135-139. Date of Electronic Publication: 2020 Jan 28 (Print Publication: 2020).
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Beilstein-Institut Country of Publication: Germany NLM ID: 101250746 Publication Model: eCollection Cited Medium: Print ISSN: 1860-5397 (Print) Linking ISSN: 18605397 NLM ISO Abbreviation: Beilstein J Org Chem Subsets: PubMed not MEDLINE
-
6دورية أكاديمية
المؤلفون: Weir HM; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom. Hazel.Weir@astrazeneca.com., Bradbury RH; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Lawson M; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Rabow AA; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Buttar D; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Callis RJ; Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Curwen JO; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., de Almeida C; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Ballard P; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Hulse M; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Donald CS; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Feron LJ; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Karoutchi G; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., MacFaul P; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Moss T; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Norman RA; Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Pearson SE; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Tonge M; Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Davies G; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Walker GE; Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Wilson Z; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Rowlinson R; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Powell S; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Sadler C; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Richmond G; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, United Kingdom., Ladd B; Oncology iMed, AstraZeneca R&D Boston, Gatehouse Drive, Waltham, Massachusetts., Pazolli E; H3 Biomedicine, Cambridge, Massachusetts., Mazzola AM; Oncology iMed, AstraZeneca R&D Boston, Gatehouse Drive, Waltham, Massachusetts., D'Cruz C; Oncology iMed, AstraZeneca R&D Boston, Gatehouse Drive, Waltham, Massachusetts., De Savi C; Oncology iMed, AstraZeneca R&D Boston, Gatehouse Drive, Waltham, Massachusetts.
المصدر: Cancer research [Cancer Res] 2016 Jun 01; Vol. 76 (11), pp. 3307-18. Date of Electronic Publication: 2016 Mar 28.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE
مواضيع طبية MeSH: Breast Neoplasms/*drug therapy , Cinnamates/*pharmacology , Estrogen Receptor Modulators/*pharmacology , Estrogen Receptor alpha/*antagonists & inhibitors , Estrogen Receptor alpha/*genetics , Indoles/*pharmacology , Mutation/*genetics, Administration, Oral ; Animals ; Apoptosis/drug effects ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Cell Proliferation/drug effects ; Cinnamates/administration & dosage ; Drug Evaluation, Preclinical ; Estrogen Receptor Modulators/administration & dosage ; Estrogen Receptor alpha/chemistry ; Female ; Humans ; Indoles/administration & dosage ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Protein Conformation ; Rats ; Tumor Cells, Cultured ; Uterus/metabolism ; Uterus/pathology ; Xenograft Model Antitumor Assays
-
7دورية أكاديمية
المؤلفون: Cogswell TJ; School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK., Donald CS; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK., Marquez R; School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK and Department of Chemistry, Xi'an Jiaotong-Liverpool University, SIP Suzhou, 215123, China. rudi.marquez@xjtlu.edu.cn.
المصدر: Organic & biomolecular chemistry [Org Biomol Chem] 2016 Jan 07; Vol. 14 (1), pp. 183-90.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101154995 Publication Model: Print Cited Medium: Internet ISSN: 1477-0539 (Electronic) Linking ISSN: 14770520 NLM ISO Abbreviation: Org Biomol Chem Subsets: MEDLINE
-
8دورية أكاديمية
المؤلفون: Lucas SC; AstraZeneca , Alderley Park, Macclesfield, SK10 4TG, United Kingdom., Moore JE; AstraZeneca , Alderley Park, Macclesfield, SK10 4TG, United Kingdom., Donald CS; AstraZeneca , Alderley Park, Macclesfield, SK10 4TG, United Kingdom., Hawkins JL; AstraZeneca , Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
المصدر: The Journal of organic chemistry [J Org Chem] 2015 Dec 18; Vol. 80 (24), pp. 12594-8. Date of Electronic Publication: 2015 Dec 02.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 2985193R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6904 (Electronic) Linking ISSN: 00223263 NLM ISO Abbreviation: J Org Chem Subsets: PubMed not MEDLINE
-
9دورية أكاديمية
المؤلفون: De Savi C; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K.; Oncology iMed, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Bradbury RH; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Rabow AA; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Norman RA; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., de Almeida C; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Andrews DM; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Ballard P; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Buttar D; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Callis RJ; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Currie GS; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Curwen JO; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Davies CD; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Donald CS; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Feron LJ; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Gingell H; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Glossop SC; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Hayter BR; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Hussain S; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Karoutchi G; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Lamont SG; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., MacFaul P; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Moss TA; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Pearson SE; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Tonge M; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Walker GE; Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Weir HM; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K., Wilson Z; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K.
المصدر: Journal of medicinal chemistry [J Med Chem] 2015 Oct 22; Vol. 58 (20), pp. 8128-40. Date of Electronic Publication: 2015 Oct 07.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
مواضيع طبية MeSH: Antineoplastic Agents/*metabolism , Cinnamates/*chemistry , Cinnamates/*metabolism , Estrogen Antagonists/*chemical synthesis , Estrogen Antagonists/*pharmacology , Estrogen Receptor Modulators/*chemical synthesis , Estrogen Receptor Modulators/*pharmacology , Indoles/*chemistry , Indoles/*metabolism, Antineoplastic Agents/chemistry ; Breast Neoplasms/drug therapy ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Clinical Trials, Phase I as Topic ; Down-Regulation/drug effects ; Drug Design ; Female ; Humans ; Injections, Intramuscular ; X-Ray Diffraction
-
10دورية أكاديمية
المؤلفون: Cogswell TJ; School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK. rudi.marquez@glasgow.ac.uk., Donald CS, Long DL, Marquez R
المصدر: Organic & biomolecular chemistry [Org Biomol Chem] 2015 Jan 21; Vol. 13 (3), pp. 717-28.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101154995 Publication Model: Print Cited Medium: Internet ISSN: 1477-0539 (Electronic) Linking ISSN: 14770520 NLM ISO Abbreviation: Org Biomol Chem Subsets: MEDLINE
مواضيع طبية MeSH: Benzaldehydes/*chemistry , Lactams/*chemical synthesis, Halogenation ; Molecular Structure ; Stereoisomerism